Jonathan Peskoff
Algemeen Directeur bij F3 Platform Biologics, Inc.
Profiel
Jonathan E.
Peskoff worked as a General Partner at NextPoint Partners.
He completed his undergraduate degree at the University of Southern California.
Actieve functies van Jonathan Peskoff
| Bedrijven | Functie | Begin |
|---|---|---|
F3 Platform Biologics, Inc.
 F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | Algemeen Directeur | 01-01-2021 |
Eerdere bekende functies van Jonathan Peskoff
| Bedrijven | Functie | Einde |
|---|---|---|
NextPoint Partners
 NextPoint Partners Investment ManagersFinance NextPoint Partners (NextPoint Partners) is a venture capital firm founded in 1990. The firm is headquartered in Washington, District of Columbia. | Private Equity Investor | 31-01-2004 |
Opleiding van Jonathan Peskoff
| University of Southern California | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
NextPoint Partners
NextPoint Partners Investment ManagersFinance NextPoint Partners (NextPoint Partners) is a venture capital firm founded in 1990. The firm is headquartered in Washington, District of Columbia. | Finance |
F3 Platform Biologics, Inc.
F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | Health Technology |
